Trial Profile
A phase Ib/II trial of the CAM-H2 targeting HER2-positive brain metastatic breast cancer
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 01 Dec 2018
Price :
$35
*
At a glance
- Drugs SGMIB anti-HER2 monoclonal antibody I-131 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2018 New trial record